Mylan N.V. announced the US launch of the oncology drug mitomycin for injection USP, 5 mg/vial, 20 mg/vial and 40 mg/vial single dose vials, a generic version of the reference listed drug, Bristol Myers Squibb's Mutamycin. The product is used in combination with other cancer medicines in the treatment of stomach and pancreatic cancers.

Mylan is offering mitomycin for injection USP, 5 mg/vial, 20 mg/vial and 40 mg/vial single dose vials to its hospital and institutional customers after an Abbreviated New Drug Application (ANDA) for the product was approved by the US Food and Drug Administration (FDA).

Mylan's injectables portfolio is one of the largest and most diversified in the industry, with approximately 80 injectable products in the US across several therapeutic areas. Mylan is also one of the largest suppliers of cancer medicines by volume in the US.

US sales for mitomycin for injection USP, 5 mg/vial, 20 mg/vial and 40 mg/vial single dose vials were approximately $59 million for the 12 months ending January 31, 2018, according to IQVIA.

Currently, Mylan has 206 ANDAs pending FDA approval representing approximately $93.8 billion in annual brand sales, according to IQVIA. Forty-six of these pending ANDAs are potential first-to-file opportunities, representing $42.2 billion in annual brand sales, for the 12 months ending December 31, 2017, according to IQVIA.

According to its indication, mitomycin injection is not recommended as a single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy.

Hemolytic Uremic Syndrome (HUS) a serious complication of chemotherapy, consisting primarily of macroangiopathic hemolytic anaemia, thrombocytopenia, and irreversible renal failure, has been reported in patients receiving systemic mitomycin. The syndrome may occur at any time during systemic therapy with mitomycin as a single agent or in combination with other cytotoxic drugs; however, most cases occur at doses = 60 mg of mitomycin. Blood product transfusion may exacerbate the symptoms associated with this syndrome. The incidence of the syndrome has not been defined.